Cardiovascular Diseases

At Herlev Hospital researchers are studying heart‑related conditions such as atrial fibrillation and in‑hospital cardiac arrest. Trials aim to compare new anticoagulants with existing therapy and to test simple interventions that could improve survival during emergencies.

  • Evaluating a novel oral anticoagulant for stroke prevention
  • Comparing resuscitation outcomes with adjunctive agents
  • Assessing safety of new blood‑thinning strategies
  • Investigating rapid‑action treatments during cardiac arrest

The department’s cardiovascular program blends cutting‑edge drug research with practical emergency care improvements.

Digestive System Diseases

The gastroenterology unit focuses on chronic inflammatory bowel conditions, including Crohn’s disease and ulcerative colitis. Ongoing studies evaluate oral therapies that aim to induce remission and maintain long‑term disease control.

  • Testing a novel oral anti‑inflammatory for ulcerative colitis
  • Assessing maintenance dosing of a Janus kinase inhibitor in Crohn’s disease
  • Monitoring safety of long‑term treatment extensions
  • Measuring patient‑reported outcomes and quality of life

These investigations seek to expand therapeutic options for patients living with digestive system disorders.

Female Urogenital Diseases and Pregnancy Complications

A targeted trial at Herlev Hospital examines care after obstetric perineal rupture. The study looks at whether a short course of oral antibiotics can lower infection rates and support better wound healing for new mothers.

  • Preventing postoperative infection in perineal tears
  • Reducing wound dehiscence through prophylactic antibiotics
  • Evaluating safety for mother and infant
  • Collecting data on recovery time and comfort

This research reflects the department’s commitment to improving maternal health outcomes.

Immune System Diseases

Investigations into the immune response are underway, featuring trials that combine experimental agents such as IO102‑IO103 with established immunotherapies like pembrolizumab. The goal is to boost tumor‑killing activity before surgery.

  • Measuring major pathological response to neoadjuvant immunotherapy
  • Comparing outcomes of combination versus standard treatment
  • Analyzing biomarkers of immune activation
  • Tracking postoperative recovery and side‑effect profile

These studies aim to refine how the immune system can be harnessed to fight cancer more effectively.

Neoplasms

The oncology‑focused projects at Herlev Hospital address solid tumours such as melanoma and squamous cell carcinoma of the head and neck. Researchers are testing whether postoperative immunotherapy can prevent disease recurrence after complete tumor removal.

  • Evaluating recurrence‑free survival with checkpoint inhibitors
  • Assessing the impact of adjuvant therapy on long‑term outcomes
  • Studying safety and tolerability in resected patients
  • Collecting quality‑of‑life data during follow‑up

The work contributes to advancing treatment standards for patients with high‑risk cancers.